Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Freilich

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Western Journal of Medicine|January 1, 1995
Vasculitis possibly confined to the small and large intestineB L Freilich, C N Bernstein
The Journal of Biological Chemistry|October 9, 2001
Microarray analysis detects novel Pax3 downstream target genesC S Mayanil, D George, L Freilich, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2015
Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 InfectionEric J Lawitz, William D O'Riordan, Armen Asatryan, et al.
Nature Medicine|July 9, 2021
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trialStephen A Harrison, Peter J Ruane, Bradley L Freilich, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Pol F Boudes, Mark G Swain, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Western Journal of Medicine|January 1, 1995
Vasculitis possibly confined to the small and large intestineB L Freilich, C N Bernstein
The Journal of Biological Chemistry|October 9, 2001
Microarray analysis detects novel Pax3 downstream target genesC S Mayanil, D George, L Freilich, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2015
Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 InfectionEric J Lawitz, William D O'Riordan, Armen Asatryan, et al.
Nature Medicine|July 9, 2021
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trialStephen A Harrison, Peter J Ruane, Bradley L Freilich, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Pol F Boudes, Mark G Swain, et al.
Pageof 1